MONISTAT® cures just as effectively
Miconazole, the active ingredient in MONISTAT®, is just as effective at curing vulvovaginal candidiasis (VVC) as fluconazole, the leading prescription pill.1
In a clinical study comparing MONISTAT® 7 to prescription fluconazole, there was no statistically significant difference in clinical cure rates at 14 days post-treatment.1
MONISTAT® relieves symptoms 4x faster*
Systemic fluconazole needs to be digested and absorbed into the bloodstream before it can begin to work. MONISTAT® begins to work on contact, curing VVC just as effectively as fluconazole while relieving symptoms much sooner.1
MONISTAT® treats more types of yeast2†
MONISTAT® is effective for both albicans and non-albicans species of yeast, and treats a broader spectrum of VVC than prescription fluconazole.
MONISTAT® may be appropriate for more patients2‡
Topical MONISTAT® may be a suitable treatment option for a wider range of women including those who are:
- taking oral contraceptives
- taking antidiabetic drugs
*Based on a clinical study with MONISTAT® 1 Combination Pack Ovule® treatment vs the leading prescription product.
†Per 2015 CDC Guidelines, options for first-line therapy of non-albicans vulvovaginal candidiasis (VVC) include longer duration therapy (7-14 days) with a non-fluconazole azole regimen.
‡2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of vulvovaginal candidiasis (VVC) in pregnant women.